drugset / Trial / NCT00558064

Filtered Trial for Amlodipine Non-responder

NCT00558064

Phase 3 Completed 531 enrolled Boehringer Ingelheim
Parallel-groupTreatment

Summary

To demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to amlodipine 5 mg alone in patients with essential hypertension and inadequately controlled with amlodipine 5 mg monotherapy.

Timeline

Start
2007-10
Primary completion
2008-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg
Subject Telmisartan Other / unclassified 40 mg

Indications